Related Experiment Video
Updated: May 1, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Treatment approaches for diffuse large B-cell lymphoma]
Abstract:
Diffuse large B-cell lymphoma(DLBCL) is the most common non-Hodgkin lymphoma, and is regarded as a heterogeneous group of lymphomas in terms of morphologic, immunologic, and cytogenetic features. The 2008 WHO classification divides DLBCL into subtypes based on clinical, morphological, immunological, and genetic features. The current standard of care for DLBCL is CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) combined with rituximab, anti-CD20 antibody, allowing many patients to achieve disease cure. Despite of recent progress in improving patient survival, clinical outcomes are still unsatisfactory for certain subtypes of DLBCL. This review outlines the current treatment strategy for DLBCL and focuses on recent clinical trials in Japan for particular subgroups of DLBCL.
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistent Cancers
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

